苯并[b]呋喃-3-乙醛 | 352434-24-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 苯并[b]呋喃-3-乙醛
• 中文别名: 苯并[B]呋喃-3-乙醛
• 英文名称: 2-(benzofuran-3-yl)acetaldehyde
• 英文别名: Benzo[b]furan-3-ylacetaldehyde；2-(1-benzofuran-3-yl)acetaldehyde
• CAS: 352434-24-3
• 化学式: C₁₀H₈O₂
• 分子量: 160.172
• InChiKey: IDIWXBHNEVHKCY-UHFFFAOYSA-N

物化性质

• 沸点：
  272.8±15.0 °C(Predicted)
• 密度：
  1.173±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  苯并[b]呋喃-3-乙醛 在 4-甲基苯磺酸吡啶 、 magnesium sulfate 、 copper(II) sulfate 、 tricyclohexylphosphine tetrafluoroborate 、 苄胺 作用下， 以 甲苯 为溶剂， 生成 (R)-N-((R)-2-(benzofuran-3-yl)-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)-2-methylpropane-2-sulfinamide
  参考文献：
  名称：

  [EN] ARTEMISININ-PROTEASOME INHIBITOR CONJUGATES AND THEIR USE IN THE TREATMENT OF DISEASE
  [FR] CONJUGUÉS D'ARTÉMISININE-INHIBITEUR DE PROTÉASOME ET LEUR UTILISATION DANS LE TRAITEMENT D'UNE MALADIE

  摘要：

  公开号：

  WO2022159581A9
• 作为产物：
  描述：

  苯并呋喃-3-乙酸 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 以98 %的产率得到苯并[b]呋喃-3-乙醛
  参考文献：
  名称：

  [EN] BORIC ACID PROTEASOME INHIBITOR AND USE THEREOF
  [FR] INHIBITEUR DE PROTÉASOME À BASE D'ACIDE BORIQUE ET SON UTILISATION
  [ZH] 一种硼酸类蛋白酶体抑制剂及其用途

  摘要：

  本发明提供了式I所示的硼酸类蛋白酶体抑制剂化合物以及其作为蛋白酶体抑制剂的应用。

  公开号：

  WO2023207889A1

文献信息

• [EN] SUBSTITUTED CARBAZOLE DERIVATIVES AND USE THEREOF IN ORGANIC ELECTRONICS<br/>[FR] DÉRIVÉS DE CARBAZOLE SUBSTITUÉS ET LEUR UTILISATION EN ÉLECTRONIQUE ORGANIQUE
  申请人：BASF SE

  公开号：WO2011125020A1

  公开（公告）日：2011-10-13

  An organic light-emitting diode, organic solar cell or switching element comprising at least one substituted carbazole derivative of the general formula (I), (II) or (III) in which X is NR4, O, S or PR4; Y is NR5, O, S or PR5; where at least one of the symbols X and Y is NR4 or NR5; R1 and R3 are each independently substituted or unsubstituted C1-C20-alkyl, substituted or unsubstituted C6-C30-aryl, substituted or unsubstituted heteroaryl having 5 to 30 ring atoms or a substituent with donor or acceptor action selected from the group consisting of C1-C20-alkoxy, C6-C30-aryloxy, C1-C20-alkylthio, C6-C30-arylthio, SiR6R7R8, halogen radicals, halogenated C1-C20-alkyl radicals, carbonyl (-CO(R6)), carbonylthio (- C = O (SR6)), carbonyloxy (- C = O(OR6)), oxycarbonyl (- OC = O(R6)), thiocarbonyl (- SC = O(R6)), amino (-NR6R7), OH, pseudohalogen radicals, amido (- C = O (NR6)), -NR6C = O (R7), phosphonate (- P(O) (OR6)2), phosphate (-OP(O) (OR6)2), phosphine (-PR6R7), phosphine oxide (-P(0)R62), sulfate (-OS(0)2OR6), sulfoxide (-S(O)R6), sulfonate (-S(O)2OR6), sulfonyl (-S(O)2R6), sulfonamide (-S(O)2NR6R7), N02, boronic esters (-OB(OR6)2), imino (-C = NR6R7), borane radicals, stannane radicals, hydrazine radicals, hydrazone radicals, oxime radicals, nitroso groups, diazo groups, vinyl groups, sulfoximines, alanes, germanes, boroximes and borazines;

  一种有机发光二极管、有机太阳能电池或开关元件，包括至少一种取代咔唑衍生物，其通用公式为(I)、(II)或(III)，其中X是NR4、O、S或PR4；Y是NR5、O、S或PR5；其中符号X和Y中至少一个是NR4或NR5；R1和R3各自独立地是取代或未取代的C1-C20-烷基，取代或未取代的C6-C30-芳基，取代或未取代的含有5到30个环原子的杂芳基，或选自C1-C20-烷氧基、C6-C30-芳氧基、C1-C20-烷硫基、C6-C30-芳硫基、SiR6R7R8、卤素自由基、卤代C1-C20-烷基自由基、羰基(-CO(R6))、硫羰基(-C=S(R6))、羰氧基(-C=O(OR6))、氧羰基(-OC=O(R6))、硫羰基(-SC=O(R6))、氨基(-NR6R7)、OH、拟卤素自由基、酰胺(-C=O(NR6))、-NR6C=O(R7)、磷酰基(-P(O)(OR6)2)、磷酸酯(-OP(O)(OR6)2)、膦(-PR6R7)、氧化膦(-P(O)R62)、硫酸酯(-OS(O)2OR6)、亚磺酰基(-S(O)R6)、磺酸酯(-S(O)2OR6)、磺酰基(-S(O)2R6)、磺酰胺(-S(O)2NR6R7)、N02、硼酸酯(-OB(OR6)2)、亚胺(-C=NR6R7)、硼烷自由基、锡烷自由基、肼自由基、腙自由基、肟自由基、亚硝基团、重氮基团、乙烯基团、亚磺酰亚胺、铝烷、锗烷、硼氧基和硼唑的取代基。
• SUBSTITUTED CARBAZOLE DERIVATIVES AND USE THEREOF IN ORGANIC ELECTRONICS
  申请人：Langer Nicolle

  公开号：US20110266528A1

  公开（公告）日：2011-11-03

  An organic light-emitting diode, organic solar cell or switching element comprising at least one substituted carbazole derivative of the general formula (I), (II) or (III) in which X is NR 4 , O, S or PR 4 ; Y is NR 5 , O, S or PR 5 ; where at least one of the symbols X and Y is NR 4 or NR 5 ; substituted carbazole derivatives of the formula (I), (II) or (III); a light-emitting layer comprising at least one substituted carbazole derivative of the general formula (I), (II) or (III) and at least one emitter material; the use of substituted carbazole derivatives of the general formula (I), (II) or (Ill) as matrix material, hole/exciton blocker material and/or electron/exciton blocker material and/or hole injection material and/or electron injection material and/or hole conductor material and/or electron conductor material in an organic light-emitting diode, an organic solar cell or in a switching element, and a device selected from the group consisting of stationary visual display units, mobile visual display units, illumination units, keyboards, garments, furniture and wallpaper comprising at least one inventive organic light-emitting diode.

  一种有机发光二极管、有机太阳能电池或开关元件，包括至少一种通式（I）、（II）或（III）的取代咔唑衍生物，其中X为NR4、O、S或PR4；Y为NR5、O、S或PR5；其中至少一个符号X和Y为NR4或NR5；通式（I）、（II）或（III）的取代咔唑衍生物；包括至少一种通式（I）、（II）或（III）的取代咔唑衍生物和至少一种发射材料的发光层；使用通式（I）、（II）或（III）的取代咔唑衍生物作为基质材料、空穴/激子阻挡材料和/或电子/激子阻挡材料和/或空穴注入材料和/或电子注入材料和/或空穴导体材料和/或电子导体材料在有机发光二极管、有机太阳能电池或开关元件中的使用，以及选自固定视觉显示单元、移动视觉显示单元、照明单元、键盘、服装、家具和包括至少一种创新有机发光二极管的壁纸的设备。
• [EN] COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS<br/>[FR] COMPOSÉS POUR LE TRAITEMENT D'INFECTIONS VIRALES PAR PARAMYXOVIRUS
  申请人：ALIOS BIOPHARMA INC

  公开号：WO2014031784A1

  公开（公告）日：2014-02-27

  Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

  本文披露了新的抗病毒化合物，以及包含一种或多种抗病毒化合物的药物组合物，并且揭示了合成这些化合物的方法。本文还披露了利用一种或多种小分子化合物改善和/或治疗副黏病毒病毒感染的方法。副黏病毒感染的例子包括由人类呼吸道合胞病毒（RSV）引起的感染。
• Piperidine-4 sulphonamide compounds
  申请人：——

  公开号：US20010034352A1

  公开（公告）日：2001-10-25

  Compound of formula (I): 1 wherein: R 1 represents hydrogen or alkyl, R 2a and R 2b represent a group selected from hydrogen, halogen, alkyl, hydroxy, alkoxy, trihaloalkyl, cyano, nitro, amino, alkylamino and dialkylamino, R 3 represents hydrogen or hydroxy, X represents oxygen or methylene, V represents an alkylene chain that is optionally unsaturated and optionally substituted, U represents a bond or an alkylene chain, W represents a group selected from aryl and heteroaryl, each of those groups being optionally substituted by one or more identical or different groups, its isomers, its hydrates, its solvates and addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in the treatment of diseases or pathological conditions in which endothelial dysfunction is known.

  化合物的结构式（I）如下所示： R1代表氢原子或烷基， R2a和R2b代表从氢、卤素、烷基、羟基、烷氧基、三卤代烷基、氰基、硝基、氨基、烷基氨基和二烷基氨基中选择的基团， R3代表氢原子或羟基， X代表氧原子或亚甲基， V代表一种可以是不饱和和可以被取代的烷基链， U代表键或烷基链， W代表从芳基和杂环芳基中选择的基团，每个基团可以被一个或多个相同或不同的基团取代， 它的异构体、水合物、溶剂合物以及与药学上可接受的酸形成的加合物。 含有这种化合物的药品对治疗已知存在内皮功能障碍的疾病或病理情况有用。
• 4-(Heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
  申请人：Heidelbaugh M. Todd

  公开号：US20060069143A1

  公开（公告）日：2006-03-30

  Compounds of Formula 1 where the variables have the meaning defined in the specification are agonists of alpha 2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha 2B and/or alpha 2C adrenergic receptors in preference over alpha 2A adrenergic receptors. Additionally some of the claimed compounds have no or only minimal cardivascular and/or sedatory activity. The compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha 2 adrenergic receptors. Compounds of Formula 1 which have no significant cardiovascular and/or sedatory activity are useful for treating pain and other conditions with minimal side effects.

  式1的化合物，其中变量的含义在规范中定义，是α2肾上腺素受体的激动剂。本公开的几种化合物对α2B和/或alpha2C肾上腺素受体具有特异性或选择性，而不是alpha2A肾上腺素受体。此外，一些声明的化合物没有或仅有最小的心血管和/或镇静作用。式1的化合物可用作哺乳动物，包括人类，治疗对α2肾上腺素受体激动剂治疗有反应的疾病和/或缓解条件的药物。具有无显著心血管和/或镇静作用的式1的化合物可用于治疗疼痛和其他具有最小副作用的疾病。